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Abstract
Increasing evidence supports the involvement of autophagy in the etiopathology of autoimmune diseases. Despite
the identification of autophagy-related protein (Atg)-5 as one of the susceptibility loci in systemic Lupus
erythematosus (SLE), the consequences of the carriage of these mutations for patients remain unclear. The present
work analyzed the association of Atg5 rs573775 single nucleotide polymorphism (SNP) with SLE susceptibility, IFNα,
TNFα and IL-10 serum levels, and clinical features, in 115 patients and 170 healthy individuals. Patients who where
carriers of the rs573775 T* minor allele presented lower IFNα levels than those with the wild genotype, whereas the
opposite result was detected for IL-10. Thus, since IL-10 production was regulated by rs1800896 polymorphisms, we
evaluated the effect of this Atg5 mutation in genetically high and low IL-10 producers. Interestingly, we found that the
rs573775 T* allele was a risk factor for SLE in carriers of the high IL-10 producer genotype, but not among
genetically low producers. Moreover, IL-10 genotype influences SLE features in patients presenting the Atg5 mutated
allele. Specifically, carriage of the rs573775 T* allele led to IL-10 upregulation, reduced IFNα and TNFα production
and a low frequency of cytopenia in patients with the high IL-10 producer genotype, whereas patients with the same
Atg5 allele that were low IL-10 producers presented reduced amounts of all these cytokines, had a lower prevalence
of anti-dsDNA antibodies and the latest onset age. In conclusion, the Atg5 rs573775 T* allele seems to influence SLE
susceptibility, cytokine production and disease features depending on other factors such as functional IL-10
genotype.
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Introduction
Systemic lupus erythematosus (SLE) is a multifactorial
autoimmune disease characterized by abnormal B and T cell
activation, cytokine dysregulation and production of
autoantibodies against cellular components generated from
dying cells [1]. The deposit of the resulting immune-complexes
can cause tissue injury in multiple organs, including skin,
muscle, joints, kidneys and heart [2]. Moreover, immune-
complexes containing autoantibodies against DNA and
ribonucleoproteins may activate the Toll-like receptors (TLR)-7
and 9 in many cell types, including monocytes, dendritic cells
(DC) and B lymphocytes, thus increasing the transcription of
multiple proinflammatory mediators and type I interferons (IFN).
In fact, IFNα secretion by plasmacytoid DC (pDC) plays a key
role in the pathology of the disease [2,3].
A number of cellular abnormalities have been observed in
SLE patients. Among them, the increased apoptosis rate and
the impaired clearance of apoptotic bodies [4,5] may cause
harmful effects, since they provide a source of autoantigens to
elicit the autoimmune response [6]. Whit this in mind, the
autophagy pathway plays a protective role, delivering signals
for the clearance of apoptotic cells as well as genomic stability
[7,8]. Autophagy is a cellular recycling process for damaged
organelles/proteins that were previously sequestered in
autophagosomes, double-membrane vacuoles whose
formation is regulated by several autophagy-related gene (Atg)
proteins, and then degraded after fusion with lysosomes [9,10].
In addition, autophagy participates in relevant immunological
functions, including pathogen elimination, antigen presentation,
lymphocyte development and inflammatory regulation [10–12].
In line with this, it has been reported that Atg5 contributes to
the clearance of apoptotic bodies [7], influences DC antigen
presentation [13] and may regulate the secretion of pro-
inflammatory cytokines [14,15].
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e78756
Accumulating evidence indicates that aberrant regulation of
autophagy-dependent functions could be a key component of
the etiology of autoimmune diseases, such as SLE [16,17]. In
this regard, a dysregulation of autophagy has been described
in T cells from lupus-prone mice and in patients with SLE [18].
In addition, serum factors, likely autoantibodies, purified from
patients with active SLE have been shown to induce autophagy
in neuroblastoma cell lines, providing a link between autophagy
and SLE [19].
More recently, genetic studies reported that mutations in
various autophagy regulators may contribute to the
pathogenesis of SLE [20]. In this context, genome-wide
association studies in different populations have linked several
single nucleotide polymorphisms (SNPs) in Atg5 to SLE
susceptibility [21–24]. Although the functional effects of these
Atg5 SNPs are yet unknown, it has been reported that altered
expression of this molecule generates autoimmunity and multi-
organ inflammation in mice [25]. Nevertheless, despite the
suggested role of autophagy in SLE pathogenesis, the
consequences of the presence of Atg5 mutations for SLE
patients remain unclear. Thus, in the present work we have
analyzed the possible association of Atg5 rs573775 SNP,
related to SLE susceptibility in large cohorts [21,26], with
serum levels of IFNα, TNFα and IL-10, pathogenic cytokines
for SLE that were usually upregulated in patients. In addition,
influence on disease susceptibility and clinical characteristics of
SLE patients were also evaluated.
Materials and Methods
Ethics statement
Ethics approval for this study was obtained from the
Regional Ethics Committee for Clinical Research (Servicio de
Salud del Principado de Asturias), according to the Declaration
of Helsinki. Written informed consent was signed from all
individuals prior to participation in the study.
SLE patients
All patients included in the study (n=115) were recruited from
the Asturian SLE Register [27,28], were all white in origin, and
fulfilled the American College of Rheumatology (ACR) criteria
for SLE [29]. Information on clinical features during the disease
course was obtained after a detailed review of clinical histories
(Table 1). At the time of sampling no patient had flares of
disease activity and they were asked precise questions
regarding the treatment received over the previous 3 months.
Sex and age-matched healthy controls (n=170) were enlisted
from the Asturian Blood Transfusion Center.
Atg5 and IL-10 genotyping
DNA was obtained from peripheral blood cells of 115 SLE
patients and 170 healthy controls by standard procedures. SNP
rs1800896 (A/G) at position -1082 on the IL-10 gene was
determined after amplification and hybridization with
fluorescent-labeled probes (LightCycler, Roche Diagnostics,
Mannheim, Germany), as previously described [30]. The
primers used were: 5’-atccaagacaacactactaaggc and 5’-
atggggtggaagaagttgaa, and the hybridization probes were
ggataggaggtcccttactttcctcttacc-F and LC Red 640-
ccctacttccccctcccaaa.
To determine the intronic SNP rs573775 (C/T) located in
Atg5 gene, DNA was amplified, then products were purified by
Exo-SAP digestion with exonuclease I (Epicentre, Madison, WI,
USA) and shrimp alkaline phosphatase (GE Healthcare,
Barcelona, Spain) and next single-base extension reactions
were performed with the SNaPshot Multiplex kit (Applied
Biosystems, Foster City, CA, USA). Samples were analyzed in
an AbiPrism 3130xl Genetic Analyzer (Applied Biosystems).
The primers used were: 5’-agaggtcaaaagccatgtcc and 5’-
cccctgaacacctttctctg; and the probe was 5´-
TTACCTATGATTGATCGTGGTGActcacagcTctctggcccca. This
probe was extended with a 5' tail (in capitals) that has no
homology with human sequences and mutated (in bold and
capital) to avoid dimer formation.
Cytokine quantification
Serum samples were collected and maintained at -80°C until
cytokine determination. IFNα levels were quantified by ELISA
(PBL Biomedical, USA) following the manufacturer’s
instructions. TNFα and IL-10 levels were determined by an in-
house ELISA as previously described [31,32]. Briefly, microtiter
wells were coated overnight with affinity purified anti-human
TNFα or anti-human IL-10 monoclonal antibody (R&D Systems,
Abingdon, UK) and blocked with 1% casein in Tris Buffered
Saline (TBS) for two hours at 37°C. Serum samples and TNFα/
IL-10 standards (R&D), diluted in blocking solution, were then
incubated for 18 hours at 4°C. After washing with TBS/Tween
20 (0.05%), wells were incubated for two hours with
biotinylated antihuman TNFα/IL-10 monoclonal antibody
(R&D), washed, incubated for one hour with streptavidin-
alkaline phosphatase conjugate and revealed using p-
nitrophenyl phosphate as substrate. Absorbance was
determined at a wavelength of 405 nm. Quantities of both
cytokines were calculated according to the corresponding
standard curves. The lower limit of detection was 3.12 pg/ml for
IFNα and 7.5 pg/ml for TNFα and IL-10.
Statistical analysis
The Kolmogorov-Smirnov test was used to assess the
normal distribution of the data. Data of cytokine serum levels
were represented by median (interquartile range) and
differences between patients and controls were assessed by
the non-parametric Mann-Whitney U-test or the Kruskal-Wallis
test. Genotype frequencies were obtained by direct counting
and their distribution between SLE patients and controls was
compared using 3 × 2 contingency tables and the χ2 test.
Association of Atg5 rs573775, IL-10 rs1800896 SNPs and their
interaction on SLE susceptibility was calculated by logistic
regression modeling adjusted for age and gender (Wald test).
Multivariate linear regression analyses were performed to
determine the influence of IL-10 and Atg5 SNPs on cytokine
serum levels in SLE patients. Models were adjusted for age
and sex and standardized linear regression coefficients (beta)
were used as an estimate of the association. The possible
effect of rs573775 - rs1800896 interaction on cytokine serum
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levels were evaluated by multivariate regression analyses. The
differences in clinical features of SLE patients on basis of
IL-10/Atg5 combined genotype were evaluated by the χ2 test
for categorical variables or the Mann Whitney U test for
continuous variables. GraphPad Prism 5 software (GraphPad
Software), SPSS 19.0 software package (SPSS Inc) and R
package 2.4.1. (www.r-project.org) were used for all
determinations and a p<0.05 was considered significant.
Results
1. IFNα and IL-10 levels were associated with Atg5
genotype in SLE patients
It has been reported that mutations in the Atg5 gene could
be a risk factor for SLE. Thus, we analyzed the possible
association of the SNP rs573775 (C>T) with serum levels of
IFNα, IL-10 and TNFα, three relevant cytokines usually
increased in this disease. Thus, 170 healthy controls and 115
SLE patients were genotyped and cytokine levels determined
in serum samples. Table 1 shows demographic and clinical
characteristics of patients included in the study.
Serum levels of IFNα and TNFα were significantly higher in
patients compared with controls [IFNα: 19.61 (44.61) vs 9.91
(11.52), p<0.001; TNFα: 41.26 (113.56) vs 18.83 (49.52),
p=0.02], whereas IL-10 were detected in SLE patients [0.23
(2.84)] but not in most healthy individuals. Grouping by
rs573775 SNP did not affect cytokine levels in controls, but
significant differences were detected in SLE patients. Figure 1
shows that presence of the Atg5 T* minor allele was associated
with lower production of IFNα (median values, CC: 31.95, CT:
18.79, TT: 6.42, pg/ml; p=0.01, Kruskal-Wallis test), while
TNFα levels, which were positively correlated with IFNα in
patients (r=0.280, p<0.01), showed a similar but not significant
trend (median values, CC: 61.19, CT: 31.73, TT: 24.99 pg/ml).
Conversely, an opposite effect was observed for IL-10, Atg5 T*
allele carrier patients presenting the highest serum levels
(median values, CC: 0.20, CT: 0.95, TT: 1.49, pg/ml; p=0.05,
Kruskal-Wallis test).
Thus, our data showed an unexpected association between
presence of the rs573775 T* mutated allele and low ability to
upregulate IFNα levels. On the contrary, this allele was related
to high amounts of IL-10, a cytokine genetically regulated by
known functional promoter polymorphisms that have been
previously associated with SLE susceptibility and/or outcome in
several populations [33].
Table 1. Demographic and clinical features of SLE patients.
Total SLE patients 115
Sex (female/male) (n) 108/7
Age at diagnosis, years (mean±SEM) 30.39 ± 1.15
Disease duration, years (mean±SEM) 12.48 ± 0.79
Clinical manifestations, n (%)  
Malar rash 68 (59.1)
Discoid lesions 23 (20.0)
Photosensitivity 65 (56.5)
Oral ulcers 46 (40.0)
Arthritis 86 (74.8)
Serositis 25 (21.7)
Cytopenia 61 (53.0)
Renal disorder 36 (31.6)
Neurological disorder 8 (7.0)
Autoantibodies, n (%)  
ANAs 113 (98.3)
Anti-dsDNA / titer, U/ml (mean±SEM) 85 (73.9)/34.19 ± 7.09
Anti-SSa 38 (33.0)
Anti-SSb 17 (14.8)
Anti-Sm 9 (7.8)
Anti-RNP 17 (14.8)
RF 23 (20.0)
Treatment, n (%)  
None or NSAIDs 19 (16.5)
Antimalarial drugs 64 (55.7)
Glucocorticoids/Dose, mg/day (mean±SEM) 63 (54.8)/7.80 ± 0.99)
Immunosuppressive drugsa 18 (15.7)
a Methotrexate, azathioprine, cyclophosphamide, cyclosporine A or mycophenolatemophetil.
dsDNA: double stranded DNA; RF: Rheumatoid factor; NSAID: non-steroidal anti-inflammatory drug.
doi: 10.1371/journal.pone.0078756.t001
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2. The effect of Atg5 alleles on SLE susceptibility was
influenced by IL-10 genotype
In view of the relationship between presence of the Atg5 T*
mutated allele and high IL-10 serum levels in SLE patients, and
given the reported association of the IL-10 rs1800896 G* allele
with high IL-10 production [34], we wanted to evaluate the
possible effect of both Atg5 and IL-10 SNPs, alone or in
combination, on SLE susceptibility. Initial analysis of the
genotypic and allelic frequencies of Atg5 and IL-10 SNPs
revealed no differences between patients and controls,
suggesting the absence of influence of both SNPs on SLE
susceptibility (Table 2). However, a significant effect of the
interaction between IL-10 rs1800896 and Atg5 rs573775 was
Figure 1.  Atg5 rs573775 SNP influences cytokine levels in SLE patients.  IFNα, TNFα and IL-10 serum levels were quantified
by ELISA techniques in individuals previously genotyped for rs573775 SNP. A) IFNα serum levels in SLE patients and controls are
shown on the basis of the Atg5 rs573775 alleles. B) IL-10 and TNFα serum levels depending on Atg5 alleles in SLE patients. Data
are shown as box plots, where the lines in the boxes represent the median, the boxes represent the 25th to 75th centiles, and the
lines outside the boxes represent the 10th and 90th centiles. Differences in cytokine serum concentration among genotypes were
analyzed by the Kruskal-Wallis test (K-W test). Significant differences between one group and the rest were evaluated by Mann-
Whitney U test (*p<0.05).
doi: 10.1371/journal.pone.0078756.g001
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observed in the multivariate analysis (Table 3). Thus, to further
specify the way of this interaction, we analyzed the influence of
Atg5 rs573775 on SLE risk in genetically high (GG/GA) and low
(AA) IL-10 producers. After grouping by IL-10 genotype (Table
4), we observed that presence of the Atg5 T* minor allele was
a risk factor for SLE in carriers of the high IL-10 producer
genotype, but not among low IL-10 producers, where it seemed
to exert the opposite effect. Accordingly, the presence of the
high IL-10 producer allele was a risk factor for SLE in carriers
of the Atg5 mutation (OR, 95% CI: 2.19, 1.05-4.57; p=0.04) but
not in Atg5 wild type individuals (OR, 95% CI: 0.54, 0.27-1.1;
p=0.09). Therefore, association of Atg5 rs573775 SNP on SLE
susceptibility could be dependent on other factors, such as the
IL-10 genotype.
3. Atg5/IL-10 combined genotype influences SLE
features
Next, in an attempt to determine the possible role of IL-10/
Atg5 genotypes in the phenotypic manifestations of lupus
disease, SLE patients were classified into four IL-10/Atg5
combined genotypes and both cytokine serum levels and
clinical features were evaluated.
Table 5 shows that carriers of the mutated Atg5 T* allele
presented significantly lower amounts of IFNα, while TNFα
presented the same trend but was not statistically significantly,
when compared with the other patients. Serum levels of IL-10,
however, were only significantly increased in patients with
mutated Atg5 and genetically high IL-10 producers. To
determine the strength of the association between circulating
cytokines and the studied genetic variants, a quantitative model
was performed for each cytokine (Table 6). According to
Table 2. Genotypic and allelic distributions of Atg5 and IL-10 SNPs in controls and SLE patients.
 Controls  SLE   
 n (%)  n (%)  p-value
Atg5 rs573775      
CC 85 (50.00)  56 (48.70)  0.725
CT 71 (41.76)  52 (45.22)   
TT 14 (8.24)  7 (6.08)   
T* allele frequency 29.12%  28.94%  0.913
IL-10 rs1800896      
AA 65 (38.23)  42 (36.52)  0.447
AG 78 (45.88)  48 (41.74)   
GG 27 (15.87)  25 (21.73)   
G* allele frequency 38.82%  42.61%  0.366
Differences were evaluated by χ2 test.
doi: 10.1371/journal.pone.0078756.t002
Table 3. Atg5 and IL-10 SNPs interaction on SLE susceptibility.
 Wald value p-value
Atg5 rs573775 3.06 0.216
IL-10 rs1800896 2.89 0.235
Atg5 rs573775 * IL-10 rs1800896 10.39 0.034
Associations were evaluated by multivariate logistic regression adjusted for sex and age. The accuracy of the model was 64.50%.
doi: 10.1371/journal.pone.0078756.t003
Table 4. Association of Atg5 rs573775 alleles on SLE susceptibility in genetically high and low IL-10 producers.
 IL-10 high (GG/AG)  IL-10 low (AA)
 Controls  SLE patients  Controls  SLE patients
 n (%)  n (%) OR (95% CI) p-value  n (%)  n (%) OR (95% CI) p-value
Atg5 wild (CC) 58 (34.1)  30 (26.1) Reference   27 (15.9)  26 (22.6) Reference  
Atg5 mutated (CT/TT) 47 (27.6)  43 (37.4) 1.912 (1.00-3.575) 0.042  38 (22.4)  16 (13.9) 0.468 (0.203-1.079) 0.075
Calculated by unconditional logistic regression modeling adjusted for sex and age. The accuracy of the models was 61.10% for IL-10 high and 60.70 % for IL-10 low.CI,
confidence interval; OR, odds ratio.
doi: 10.1371/journal.pone.0078756.t004
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previous data (Figure 1), Atg5 rs573775 significantly
influences, but in an opposite way, IFNα and IL-10 levels,
whereas a clear trend was detected for TNFα. Conversely,
IL-10 rs1800896 only showed a significant influence on IFNα
levels. However, we did not find significant effect of the
rs573775 - rs1800896 interaction on such cytokine serum
levels. On the other hand, the analysis of clinical characteristics
(Table 7) showed that high IL-10 producers carriers of the Atg5
T* allele presented significantly lower prevalence of cytopenia
and a trend of less renal disorder compared with the other
genotypes. However, patients with the Atg5 mutated allele and
carriers of the low IL-10 producer genotype were oldest at
diagnosis and presented a clear trend toward a lower
frequency of anti-dsDNA autoantibodies.
Therefore, the presence of the Atg5 mutated allele seems to
be associated with specific clinical and immunological features
Table 5. Cytokine serum levels in SLE patients with different IL-10/Atg5 genotype.
Combined genotype IFNα (pg/ml) TNFα (pg/ml) IL-10 (pg/ml)
IL-10 high / Atg5 mutated 17.13 (35.19)a 31.01 (83.86)c 1.40 (2.89)e
IL-10 low / Atg5 mutated 15.50 (46.75)a 32.29 (97.65)c 0.41 (1.83)
IL-10 high / Atg5 wild 46.58 (241.95)b 60.98 (113.92)d 0.20 (0.84)
IL-10 low / Atg5 wild 23.19 (95.00)b 88.15 (169.39)d 0.20 (2.28)
Values are median (interquartile range). Differences were evaluated by Mann-Whitney U test between the following groups:
a vs b: p=0.010
c vs d: p=0.130
e vs others: p=0.022
doi: 10.1371/journal.pone.0078756.t005
Table 6. Influence of Atg5 and IL-10 SNPs on cytokine serum levels in SLE patients.
 IFNα  TNFα  IL-10
 
Standardized linear regression
coefficient p-value 
Standardized linear regression
coefficient p-value 
Standardized linear regression
coefficient p-value
Atg5 rs573775 -0.271 0.007  -0.186 0.052  0.252 0.015
IL-10 rs1800896 0.212 0.033  0.133 0.163  -0.014 0.894
Sex 0.022 0.825  -0.003 0.973  -0.033 0.746
Age -0.178 0.072  -0.003 0.977  -0.034 0.740
Differences were evaluated by multivariate linear regression analysis using IFNα, TNFα or IL-10 levels as the dependent variable and adjusted for age and sex.
doi: 10.1371/journal.pone.0078756.t006
Table 7. Clinical features of SLE patients according to IL-10/Atg5 combined genotype.
 IL-10 high / Atg5 mutated IL-10 low / Atg5 mutated IL-10 high / Atg5 wild IL-10 low / Atg5 wild
 n=43 n=16 n=30 n=26
Age at diagnosis, years (mean±SEM) 30.21 (0.37) 36.69 (0.58)3 29.33 (0.44) 28.04 (0.46)
Clinical manifestations, n (%)     
Malar rash 22 (52.16) 10 (62.50) 19 (63.33) 17 (65.38)
Discoid lesions 9 (20.93) 3 (18.75) 4 (13.33) 7 (26.92)
Photosensitivity 23 (53.49) 10 (62.50) 15 (50.00) 17 (65.38)
Oral ulcers 13 (30.23) 7 (43.75) 12 (40.00) 14 (53.85)
Arthritis 33 (76.74) 11 (68.75) 25 (83.33) 17 (65.38)
Serositis 11 (25.58) 2 (12.50) 5 (16.67) 7 (26.92)
Cytopenia 16 (38.09)1 10 (62.50) 18 (60.00) 17 (65.38)
Renal disorder 9 (20.93)2 6 (37.50) 9 (30.00) 12 (46.15)
Neurological disorder 4 (9.30) 2 (12.50) 0 (0.00) 2 (7.69)
Anti-dsDNA 32 (74.42) 9 (56.25)4 24 (80.00) 20 (76.92)
Differences were evaluated by the χ2 test (categorical variables) or the Mann Whitney U test (continuous variables) between patients carriers of the indicated genotype and
the rest 1:p= 0.012 2,p= 0.064 3,p= 0.017 4,p= 0.083.
doi: 10.1371/journal.pone.0078756.t007
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in patients with SLE, but differs depending on the functional
IL-10 genotype (Figure 2). Thus, presence of the Atg5 T* allele
in combination with the high IL-10 genotype was associated
with the highest IL-10 levels, reduced production of IFNα and
TNFα and the lowest frequency of hematological and renal
disorder, whereas carriers of the same mutation but in the
presence of the low IL-10 genotype showed lower levels of all
the studied cytokines, less frequency of anti-dsDNA antibodies
and delayed onset of the disease, in accordance with the lower
frequency of this genotype in SLE patients.
Discussion
Alterations in autophagy and in several Atg regulatory
proteins are supposed to have a role in the etiology of
autoimmune disorders [25]. However, although genome-wide
association studies showed that various SNPs in the Atg5
locus were associated with SLE susceptibility [21–24], the
possible effects of such genetic variations in SLE patients are
currently unknown.
In the present work we describe, for the first time, an
interesting relationship between an Atg5 SNP and cytokine
serum levels of SLE patients. Specifically, carriers of the
rs573775 T* minor allele, previously associated with SLE
susceptibility in two large cohorts [21,26], presented lower IFNα
and higher IL-10 levels than patient carriers of the wild
genotype. In addition, a slight trend towards lower production of
TNFα, a cytokine positively correlated with IFNα in SLE
patients was also observed. In accordance with these results, it
has been reported that disruption of basal autophagy can
reduce the induction of type I IFN in murine pDCs [35] and the
production of TNFα by human peripheral blood mononuclear
cells [36]. Since an increased production of IFNα, probably by
pDC, is a key feature in the etiopathogenesis of SLE, this
association between a putative SLE risk factor and low IFNα
levels might seem contradictory. Some evidence, however,
suggests it is consistent. It has been reported that the
autophagy process participates in the induction of type I IFNs
in pDC upon binding of nucleic acids to the TLR7/9 [35].
Moreover, the most pronounced defect of mice with DC-
conditional deletion in Atg5 was the processing and
presentation of phagocytosed antigens containing TLR stimuli
for MHC class II, then failing to mount a proper Th1 cell
immune response [13]. In addition, Atg5 could play a role in
non-canonical autophagy that mediates IFNα secretion in
response to DNA-immune complexes [37,38]. Therefore, Atg5-
mediated alterations in autophagy may impair the activation of
DCs through the immune complexes present in SLE patients,
thus preventing the production IFNα and the activation of NF-
κB, a pathway involved in the transcription of Th1-promoting
cytokines, TNFα and other proinflammatory mediators.
On the other hand, our results might suggest that Atg5
mutation in SLE patients prompts the upregulation of IL-10,
usually increased in these patients and associated with
indicators of disease activity [39]. This cytokine promotes B-
cell-mediated functions, enhancing survival, proliferation,
differentiation and antibody production, thus explaining B cell
hyperactivity and autoantibody production, two main features of
Figure 2.  Effects of Atg5 and IL-10 SNPs on SLE risk, cytokine levels and clinical features.  The diagram represents a model
of the effects of Atg5 rs573775 and the functional IL-10 polymorphisms (low/high genetic producers) on SLE, which were supported
by our results. A significant influence of both SNPs was detected, however, Atg5 rs573775 showed a dominant role.
doi: 10.1371/journal.pone.0078756.g002
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SLE. It is known that IL-10 has a predominant opposite effect
to TNFα in systemic inflammatory responses, both cytokines
being mutually regulated in physiological conditions. It is worth
noting that functional IL-10 SNPs, especially rs1800896, have
been associated in several populations with SLE susceptibility
or clinical outcome [33], although conclusive data have not
been obtained. Thus, at this point, it seems reasonable to think
that IL-10 and Atg5 SNPs could exert a combined effect on
SLE disease.
With regard to the association of IL-10 rs1800896 and Atg5
rs573775 SNPs to SLE susceptibility, no significant differences
in allelic or genotypic frequencies were observed in our cohort
between patients and controls. The IL-10 gene is situated in a
major SLE susceptibility locus (1q31-32), however, in spite of
the considerable number of studies performed, no definitive
result about its involvement on SLE susceptibility was achieved
[33], which could be due, at least in part, to the differences in
the frequencies of the IL-10 rs1800896 alleles among
populations. In a similar way, the studies on the involvement of
several Atg5 SNPs showed inconclusive results, although the
Atg5 rs573775 T* allele has been found significantly associated
with SLE susceptibility, at a low rate (OR: 1.17 and 1.19), in
two large cohorts that included different populations [21,26].
Our results could shed some light on this matter, since we
observed that the association of Atg5 SNP with SLE
susceptibility may be dependent on other factors, such as the
IL-10 genotype. The present work indicates that the Atg5
rs573775 T* allele was a risk factor for SLE in carriers of the
IL-10 rs1800896 G* high producer allele, but not among
genetically low IL-10 producers. Interestingly, in our Spanish
population, like in other South European countries, the IL-10 G*
allele was underrepresented compared with North/Central
European and North American populations [33]. These
differences could explain the lack of a significant association of
the Atg5 rs573775 SNP with susceptibility when analyzing our
entire population, in which about 60% of individuals are high
IL-10 producers whereas in North/Central Europeans they may
represent 75%. It is of note, Alonso-Perez et al. [26] showed
that this Atg5 SNP was more associated with SLE susceptibility
in Central than in Southern Europeans (OR, 95% CI: 1.36,
1.10-1.68 and 1.11, 0.98-1.26 , respectively), in accordance
with the frequency of genetically high IL-10 producers reported
in these populations.
Hence, in spite of the lack of IFNα induction, the Atg5
mutation was a risk factor for SLE when high IL-10 levels are
available. In line with this, our results showed that genetically
high IL-10 producer patients presented high serum levels of
this cytokine when the Atg5 mutated allele was present, but not
in Atg5 wild type individuals. Accordingly, the linear multivariate
regression model performed in this work suggests that Atg5
mutation, rather than IL-10 SNP, exerts a relevant role in the
prediction of IL-10 serum levels. Therefore, cytokine levels of
SLE patients classified in the four combined IL-10/Atg5
genotypes suggested that those with normal autophagy
function (Atg5 wild type), regardless of their IL-10 genotype,
produced enough TNFα to counterbalance IL-10 levels,
whereas Atg5 mutated patients were unable to control the
genetically high IL-10 production (Table 5). In addition, it has
been reported that IL-10 and other Th2 cytokines may inhibit
the induction of autophagy in several immune cells [40,41],
thus enhancing the effect of Atg5 mutation on SLE
susceptibility.
Finally, the combined IL-10/Atg5 genotypes also showed an
impact on the clinical characteristics of lupus disease.
Intriguingly, IL-10 genotype seems to influence the outcome of
SLE patients who are carriers of the Atg5 mutated allele. Thus,
high IL-10 producers mutated for Atg5 exhibited the lowest
frequency of cytopenia, suggesting an effect of this cytokine in
increasing the survival of activated lymphocytes. In this sense,
since autophagy is able to regulate cell death in activated T
cells [42,43], the presence of an altered Atg5 function in
patients carriers of the mutated allele could favor the
maintenance and activation of autoreactive lymphocytes in
SLE. On the other hand, low IL-10 producer patients mutated
for Atg5 displayed the lowest amount of anti-dsDNA antibodies
and later onset of the disease. These features could be
explained by the low serum levels of IL-10, IFNα, TNFα, and
probably other cytokines, together with the altered autophagy
function present in patients with this genotype, which were
slightly underrepresented in our population compared with
controls.
In conclusion, this is the first study carried out in SLE
patients that has analyzed the influence of functional IL-10
genotype on the effect of Atg5 mutation, two molecules
previously associated with susceptibility or outcome of the
disease. We found that Atg5 mutation was a risk factor for SLE
in carriers of the high IL-10 producer allele, leading to high
IL-10 and low IFNα production and low frequency of cytopenia.
Contrary, presence of this Atg5 mutation in low IL-10 producers
did not increase SLE risk, patients with this genotype exhibiting
low amounts of the analyzed cytokines, the lowest prevalence
of anti-dsDNA antibodies and a delay in the age at diagnosis
(Figure 2).
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